ALK and non-small cell lung carcinoma: Two appraisals included four health transitions (progression free, non-central nervous system (CNS) progression, CNS progression and death) instead of three, these concerned PartSA models for both alectinib and brigatinib for the treatment of first line ALK-positive NSCLC (TA536 and TA670).